文献速递慢阻肺

COPD急性加重与维持治疗期间肺功能下降的关联

Association between COPD exacerbations and lung function decline during maintenance therapy.
PubMed 文献 · Thorax · 2020-06-12

本研究基于英国两个大型电子病历数据库,纳入12178例轻中度COPD患者,随访至少3年,探讨急性加重频率与FEV1下降的关系及吸入糖皮质激素(ICS)和血嗜酸性粒细胞计数(BEC)的影响。结果显示,在BEC≥350 cells/µL且未使用ICS的患者中,每次急性加重与FEV1下降加速19.4 mL/年相关,而ICS治疗可减弱这一效应。

要点

  • BEC≥350 cells/µL未用ICS者,每次急性加重FEV1多降19.4 mL/年。
  • ICS治疗使上述额外下降减少15.1 mL/年,降至4.3 mL/年。
  • 高BEC患者更积极预防急性加重或可延缓肺功能丢失。

核心结论

  • 在BEC≥350 cells/µL且未使用ICS的COPD患者中,急性加重与更快的FEV1下降相关。
  • ICS治疗可减弱高BEC患者急性加重相关的额外肺功能下降。

研究设计与样本

  • 前瞻性观察性研究,使用英国CPRD和OPCRD两个大型电子病历数据库。
  • 纳入年龄≥35岁、有吸烟史的轻中度COPD患者,随访至少3年,共12178例,平均年龄66岁,女性48%。
  • 采用多水平混合效应线性回归模型分析年急性加重率与FEV1下降的关系,并通过交互项研究血嗜酸性粒细胞的效应修饰。

主要发现

  • 8981例(74%)患者接受ICS治疗。
  • 在BEC≥350 cells/µL未使用ICS的患者中,每次急性加重与后续FEV1下降加速19.4 mL/年相关(95% CI 12.0 to 26.7,p<0.0001)。
  • 在BEC≥350 cells/µL使用ICS的患者中,该额外下降减少15.1 mL/年(6.6 to 23.6),降至4.3 mL/年(1.9 to 6.7,p<0.0001)。

关键数值与推荐

  • BEC≥350 cells/µL未用ICS者,每次急性加重FEV1下降加速19.4 mL/年(95% CI 12.0 to 26.7,p<0.0001)。
  • BEC≥350 cells/µL使用ICS者,额外下降减少15.1 mL/年(6.6 to 23.6),降至4.3 mL/年(1.9 to 6.7,p<0.0001)。

临床怎么用

  • 对BEC≥350 cells/µL的COPD患者,应考虑使用ICS以预防急性加重并减缓肺功能下降。
  • 临床中需关注急性加重频率对肺功能的影响,尤其在高BEC患者中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the impact of exacerbations on COPD progression or whether inhaled corticosteroid (ICS) use and blood eosinophil count (BEC) affect progression. We aimed to assess this in a prospective observational study. METHODS: The study population included patients with mild to moderate COPD, aged ≥35 years, with a smoking history, who were followed up for ≥3 years from first to last spirometry recording using two large UK electronic medical record databases: Clinical Practice Research Datalink (CPRD) and Optimum Patient Care Research Database (OPCRD). Multilevel mixed-effects linear regression models were used to determine the relationship between annual exacerbation rate following initiation of therapy (ICS vs non-ICS) and FEV1 decline. Effect modification by blood eosinophils was studied through interaction terms. RESULTS: Of 12178 patients included (mean age 66 years; 48% female), 8981 (74%) received ICS. In patients with BEC ≥350 cells/µL not on ICS, each exacerbation was associated with subsequent acceleration of FEV1 decline of 19.4 mL/year (95% CI 12.0 to 26.7, p<0.0001). This excess decline was reduced by 15.1 mL/year (6.6 to 23.6) to 4.3 mL/year (1.9 to 6.7, p<0.0001) in those with BEC ≥350 cells/µL treated with ICS. CONCLUSION: Exacerbations are associated with a more rapid loss of lung function among COPD patients with elevated blood eosinophils, defined as ≥350 cells/µL, not treated with ICS. More aggressive prevention of exacerbations using ICS in such patients may prevent excess loss of lung function.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Kerkhof M, Voorham J, Dorinsky P, et al. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax. 2020. PMID: 32532852. doi:10.1136/thoraxjnl-2019-214457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。